Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks

Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks

Key PointsNovo Nordisk is dropping its lawsuit against Hims & Hers Health, as it has reached an agreement with the telehealth company.The deal will permit Hims & Hers Health to sell Ozempic and Wegovy on its platform.It eliminates risk for Hims & Hers Health and could lead to better sales numbers for the popular GLP-1 drugs.10 stocks we like better than Novo Nordisk › To say that pharmaceutical giant Novo Nordisk (NYSE: NVO) has had a tumultuous…

Hims & Hers Battle with Novo Nordisk Takes Surprising Turn

The dispute between telehealth provider Hims & Hers and Danish drugmaker Novo Nordisk over weight-loss drugs appears to have taken an unexpected turn.